David Heimbrook
Publications by Year
Research Areas
Melanoma and MAPK Pathways, Synthesis and biological activity, Cancer Mechanisms and Therapy, Protein Kinase Regulation and GTPase Signaling, Cancer-related Molecular Pathways
Most-Cited Works
- → Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1(2006)811 cited
- → Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapy(2006)700 cited
- → RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models(2010)402 cited
- Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.(2001)
- → Phosphorylation of p53 on Key Serines Is Dispensable for Transcriptional Activation and Apoptosis(2004)233 cited
- → Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer(2011)216 cited
- → Activation of p53 by MDM2 Antagonists Can Protect Proliferating Cells from Mitotic Inhibitors(2005)201 cited
- → Cloning and characterization of E2F-2, a novel protein with the biochemical properties of transcription factor E2F.(1993)193 cited
- → Stereochemistry and deuterium isotope effects in camphor hydroxylation by the cytochrome P450cam monooxygenase system(1982)192 cited
- → Preclinical Profile of a Potent γ-Secretase Inhibitor Targeting Notch Signaling with In vivo Efficacy and Pharmacodynamic Properties(2009)189 cited